Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug
Biogen is urging Medicare to broadly reimburse its Alzheimer's drug Aduhelnm, in response to a proposal by the US Centers for Medicaid and Medicare Services (CMS) to sharply limit coverage of new drugs for the disease...
February 11, 2022
by FirstWordPharma
Samsung Biologics to buy out Biogen's stake in Samsung Bioepis
Samsung Biologics has reached an agreement for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.
January 29, 2022
by CPhIonline
Samsung Biologics to acquire Biogen’s stake in Samsung Bioepis for $2.3bn
Biogen is eligible to receive up to $50m from Samsung Biologics on meeting some commercial milestones.
January 29, 2022
by Pharmaceutical-Technology
Samsung Biologics Acquires Full Ownership of Samsung Bioepis
Buys out Biogen’s stake in the joint venture for $2.3 billion.
January 29, 2022
by contractpharma
Biogen to obtain licence for Ionis’ investigational SMA therapy
Biogen will handle the expenses associated with the development, production and potential marketing of BIIB115.
January 6, 2022
by Pharmaceutical-Technology
Biogen Exercises Option for Exclusive License to BIIB115
BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy.
January 4, 2022
by contractpharma
Biogen announces results from Phase IIIb NOVA study for MS
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
August 6, 2021
by europeanpharmaceuticalreview
Alzheimer’s Disease - Recent Advances in Treatment
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
August 6, 2021
by Neeta Ratanghayra
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
July 30, 2021
by europeanpharmaceuticalreview
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
July 26, 2021
by PharmaSources/Dopine
Former FDA adviser calls for wider probe into Biogen Alzheimer’s drug approval
A federal probe of the US Food and Drug Administration’s approval of a controversial new Alzheimer’s disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said 20th.
July 22, 2021
by expresspharma
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
Mirimus, Inc., today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
July 22, 2021
by prnewswire